Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Medtronic PLC pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Common-Size Income Statement
- Analysis of Reportable Segments
- Analysis of Geographic Areas
- Enterprise Value to EBITDA (EV/EBITDA)
- Selected Financial Data since 2005
- Return on Equity (ROE) since 2005
- Current Ratio since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Medtronic PLC for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
The analysis of the quarterly financial ratios over the observed periods reveals distinct trends in asset utilization and equity efficiency.
- Net Fixed Asset Turnover
- This ratio exhibited a gradual decline from the initial value of 5.72 to 4.85 over the examined timeframe. The highest recorded value was 6.13 in October 2021, followed by a steady decreasing trend. This downward movement suggests a diminishing efficiency in generating revenue from fixed assets, which may imply aging assets, reduced sales relative to fixed asset base, or increased investment in fixed assets not yet yielding equivalent revenue.
- Total Asset Turnover
- The total asset turnover ratio showed a generally stable to slightly increasing pattern. Starting at 0.30, it fluctuated mildly but trended upward towards 0.38 by the end of the period. This indicates improved overall utilization of total assets in generating sales, reflecting possibly better asset management or increased sales with relatively stable asset levels.
- Equity Turnover
- Equity turnover demonstrated a continuous incremental trend from 0.56 up to 0.71. This steady rise indicates improved productivity of equity in generating revenue, which might be attributed to augmented sales or more efficient equity utilization. The consistent growth suggests strengthening return dynamics on shareholders’ equity over the time horizon.
In summary, while the efficiency of fixed assets in producing sales showed a decline, the overall asset and equity utilization improved, indicating differentiated performance across asset categories. The rising total asset and equity turnovers suggest enhanced operational efficiency in utilizing these resources to generate revenues despite the lower fixed asset turnover. These insights can guide strategic focus towards optimizing fixed asset usage and sustaining the upward momentum in total and equity turnover ratios.
Net Fixed Asset Turnover
| Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
| Net sales | |||||||||||||||||||||||||||||
| Property, plant, and equipment, net | |||||||||||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||||||||||
| Net fixed asset turnover1 | |||||||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
1 Q2 2026 Calculation
Net fixed asset turnover
= (Net salesQ2 2026
+ Net salesQ1 2026
+ Net salesQ4 2025
+ Net salesQ3 2025)
÷ Property, plant, and equipment, net
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial data reveals key insights into sales performance, asset base developments, and efficiency in asset utilization over the observed periods.
- Net Sales
- The net sales figures show some fluctuations but generally exhibit an upward tendency over time. Starting at $6,507 million in July 2020, sales peaked multiple times, notably reaching $8,589 million in April 2024 and $8,961 million by October 2025. Despite these increases, there are intermittent periods of decline or stagnation, such as a dip from $8,188 million in April 2021 to $7,847 million in October 2021, and another moderate decrease observed around mid-2024. Overall, net sales demonstrate resilience with a trend toward gradual growth across the span of the data.
- Property, Plant, and Equipment, Net
- The net value of property, plant, and equipment consistently increases throughout the periods. Beginning at $4,882 million in July 2020, the asset base expands steadily to $7,164 million by October 2025. This steady growth implies ongoing capital investments and asset accumulation efforts over the years, reflecting a possibly strategic approach to capacity expansion or modernization. No significant downturns are observed in this asset category, indicating stability in the company's fixed asset base.
- Net Fixed Asset Turnover Ratio
- The net fixed asset turnover ratio, which measures the efficiency of the company in utilizing its fixed assets to generate sales, displays a declining trend. Starting with a ratio of 5.72 in July 2020, it gradually diminishes to 4.85 by October 2025. This steady decline suggests that while both sales and fixed assets have increased, the asset base has grown at a faster pace relative to sales, potentially indicating decreasing efficiency or diminishing returns on new fixed asset investments.
In summary, although the company successfully increased its net sales and expanded its asset base over the analyzed timeframe, the decreasing net fixed asset turnover ratio points to a relative reduction in asset utilization efficiency. This trend could warrant further investigation to determine the underlying causes, such as whether new assets are not fully integrated into revenue-generating operations or if market factors are impacting sales growth relative to asset investments.
Total Asset Turnover
| Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
| Net sales | |||||||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||||||||||
| Total asset turnover1 | |||||||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Total Asset Turnover, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
1 Q2 2026 Calculation
Total asset turnover
= (Net salesQ2 2026
+ Net salesQ1 2026
+ Net salesQ4 2025
+ Net salesQ3 2025)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial analysis reveals several noteworthy trends and patterns over the examined periods.
- Net Sales
- Net sales exhibit a general upward trajectory with some fluctuations. Initial quarters show a steady increase from 6,507 million US dollars to a peak around 8,188 million in April 2021. Thereafter, sales fluctuate within the range of approximately 7,300 to 8,900 million US dollars. The most recent data points confirm continued sales growth, reaching near 8,961 million US dollars by October 2025, suggesting resilience and positive market demand over time.
- Total Assets
- Total assets fluctuate moderately throughout the periods, ranging mostly between 89,000 million and 94,000 million US dollars. Starting around 93,906 million US dollars, assets peaked slightly above 94,000 million in early 2023, followed by a gradual decline into the low 90,000 millions. Despite minor volatility, the asset base appears relatively stable, with no significant expansion or contraction trends over the time frame.
- Total Asset Turnover
- The total asset turnover ratio demonstrates a consistent improvement trend, moving upward from 0.30 initially to 0.38 by the end of the latest period. This increase suggests enhanced efficiency in utilizing assets to generate sales, pointing toward improved operational performance. The ratio’s steady rise further corroborates the positive sales trend and indicates more effective asset management.
Overall, the data imply a growing revenue base with stable asset levels complemented by increasing efficiency in asset utilization. These patterns collectively indicate a strengthening operational position over the analyzed quarters.
Equity Turnover
| Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
| Net sales | |||||||||||||||||||||||||||||
| Shareholders’ equity | |||||||||||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||||||||||
| Equity turnover1 | |||||||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Equity Turnover, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
1 Q2 2026 Calculation
Equity turnover
= (Net salesQ2 2026
+ Net salesQ1 2026
+ Net salesQ4 2025
+ Net salesQ3 2025)
÷ Shareholders’ equity
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial data reveals several notable trends over the analyzed periods. Net sales demonstrate a fluctuating yet generally increasing trend, with occasional declines observed in some quarters. Initially, net sales increased from 6,507 million USD to a peak of 8,188 million USD within the first year, followed by some variability including dips, but ultimately reaching a higher endpoint of approximately 8,961 million USD by the final quarter.
Shareholders' equity reflects a slight declining pattern over the entire time span. Starting from 50,296 million USD, the equity exhibits minor fluctuations but shows an overall downward trajectory, ending near 48,652 million USD. This decrease suggests either distributions to shareholders, losses, or other equity-reducing activities outweighing equity growth.
Equity turnover illustrates the company's increasing efficiency in utilizing equity to generate sales. The ratio moved upward from 0.56 to 0.71, indicating a progressive improvement in the frequency with which equity contributes to net sales. This suggests enhanced operational performance or asset management effectiveness over time.
- Net Sales
- Displayed variability with an overall upward trend, increasing from 6.5 billion USD to nearly 9 billion USD, indicating growing revenue generation capacity with intermittent quarters of decline.
- Shareholders’ Equity
- Showed a mild but consistent downward trend from approximately 50.3 billion USD to 48.7 billion USD, implying possible shareholder distributions, repurchases, or decreased retained earnings during the period.
- Equity Turnover
- Progressively improved from 0.56 to 0.71, signifying better utilization of equity to produce sales, reflective of operational effectiveness or increased asset turnover.